Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OABI 
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: OABI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.74% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 246.16M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 8 | Beta 0.93 | 52 Weeks Range 1.22 - 4.17 | Updated Date 12/3/2025 |
52 Weeks Range 1.22 - 4.17 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.136 | Actual -0.14 |
Profitability
Profit Margin - | Operating Margin (TTM) -810.18% |
Management Effectiveness
Return on Assets (TTM) -12.69% | Return on Equity (TTM) -22.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 222128274 | Price to Sales(TTM) 11.67 |
Enterprise Value 222128274 | Price to Sales(TTM) 11.67 | ||
Enterprise Value to Revenue 10.53 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 143955400 | Shares Floating 96794171 |
Shares Outstanding 143955400 | Shares Floating 96794171 | ||
Percent Insiders 12.72 | Percent Institutions 55.82 |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc., formerly Ligand subsidiary, was spun out to be its own publicly traded company in 2022. They provide antibody discovery technology, offering access to diverse antibody repertoires and engineering capabilities.
Core Business Areas
- Antibody Discovery Technology: Provides platforms for generating diverse panels of antibodies, including OmniAb, OmniClic, OmniFlic, OmniDeep, and OmniTaur.
- Therapeutic Antibody Discovery and Development: Partners with pharmaceutical companies to develop therapeutic antibodies for various diseases.
- Licensing and Royalties: Generates revenue through licensing its antibody discovery platforms and receiving royalties on partnered therapeutic antibodies.
Leadership and Structure
Matt Foehr is the President and CEO. The company has a board of directors and various functional departments focused on R&D, business development, and operations.
Top Products and Market Share
Key Offerings
- OmniAb Platform: A suite of transgenic animals that can be used to discover fully human antibodies. Includes OmniRat, OmniMouse, OmniChicken, and OmniTaur. Revenue is generated via upfront fees, milestones, and royalties. Competitors include Harbour BioMed (HBM), Trianni (acquired by Charles River Laboratories).
- OmniClic: A fully human B cell cloning platform that enables the discovery of antibodies from immunized animals or humans. Revenue is generated via upfront fees, milestones, and royalties. Competitors include Adaptive Biotechnologies (ADPT) and iRepertoire.
- OmniFlic: A bispecific antibody platform. Revenue is generated via upfront fees, milestones, and royalties. Competitors include Regeneron (REGN) and Genmab (GMAB).
Market Dynamics
Industry Overview
The antibody discovery market is growing, driven by the increasing demand for antibody-based therapeutics. Biopharma companies are seeking novel platforms and technologies to accelerate antibody discovery and development.
Positioning
OmniAb is positioned as a leading provider of antibody discovery technology, offering diverse and proprietary platforms that enable the generation of high-quality antibodies. It has a strong patent portfolio and established partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for antibody discovery is estimated to be billions of dollars. OmniAb is positioned to capture a significant share of this market through its diverse technology platforms and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Diverse and proprietary antibody discovery platforms
- Strong patent portfolio
- Established partnerships with major pharmaceutical companies
- Experienced management team
Weaknesses
- Dependence on licensing revenue
- Competition from other antibody discovery technology providers
- Risks associated with drug development
- Relatively small market capitalization
Opportunities
- Expanding into new therapeutic areas
- Developing new antibody discovery platforms
- Acquiring complementary technologies
- Increasing adoption of antibody-based therapeutics
Threats
- Competition from larger pharmaceutical companies
- Technological advancements that could render OmniAb's platforms obsolete
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Adaptive Biotechnologies (ADPT)
- Charles River Laboratories (CRL)
- Regeneron Pharmaceuticals (REGN)
- Genmab (GMAB)
- Ligand Pharmaceuticals (LGND)
Competitive Landscape
OmniAb competes with other antibody discovery technology providers and pharmaceutical companies. Its advantages include its diverse technology platforms and strong patent portfolio. Disadvantages include its relatively small size and dependence on licensing revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the recent spin-off.
Future Projections: Future growth is projected to be driven by the increasing demand for antibody-based therapeutics and the adoption of OmniAb's technology platforms.
Recent Initiatives: Focusing on expanding its technology offerings and strengthening its partnerships with pharmaceutical companies.
Summary
OmniAb is a biotechnology company with potential, offering cutting-edge antibody discovery platforms. Its success hinges on effective partnerships and continued innovation in the rapidly evolving biopharmaceutical landscape. The company's dependence on licensing and royalties is a risk. OmniAb needs to demonstrate consistent revenue growth and profitability to solidify its position in the competitive market. Continued strategic alliances are crucial to increasing revenue. As a new company, monitoring its cash flow and expenditures will be critical.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OmniAb Inc. Investor Relations
- SEC Filings
- Third-party industry reports
- Company press releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. The AI-based rating is based on a specific algorithm and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.